NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
Meanwhile, Lilly gets in on the next-gen KRAS action.
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
But will the FDA accept the surrogate endpoint used in ASC4First?
